Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Microbiol Resour Announc ; 9(23)2020 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-32499357

RESUMEN

Mycobacteriophages Joselito, Patt, and Tydolla were isolated from different soil or water samples using Mycobacterium smegmatis mc2155 as the host. Each was obtained using direct isolation techniques, purified, and then sequenced using the deconvolution of genomes after en masse sequencing (DOGEMS) method.

2.
Microbiol Resour Announc ; 9(45)2020 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-33154015

RESUMEN

Apex and Gophee are mycobacteriophages directly isolated from soil using the host Mycobacterium smegmatis mc2155. Apex has a 71,244-bp double-stranded DNA (dsDNA) genome encoding 98 putative proteins, and Gophee has a 68,556-bp dsDNA genome encoding 101 putative proteins.

3.
Microbiol Resour Announc ; 8(32)2019 Aug 08.
Artículo en Inglés | MEDLINE | ID: mdl-31395640

RESUMEN

EleanorGeorge, Mattes, and Spikelee are mycobacteriophages isolated from different soil samples using Mycobacterium smegmatis mc2155 as the host. Each was obtained using direct isolation techniques, purified, and then sequenced. Based on sequence similarity, all three belong to the F1 subcluster and are temperate phages.

4.
Clin Vaccine Immunol ; 13(9): 1052-6, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16960118

RESUMEN

Since 1989, we have been involved in the development of a vaccine against Haemophilus influenzae type b. The new vaccine is based on the conjugation of synthetic oligosaccharides to tetanus toxoid. Our main goals have been (i) to verify the feasibility of using the synthetic antigen and (ii) to search for new production alternatives for this important infant vaccine. Overall, eight trials have already been conducted with adults, children (4 to 5 years old), and infants. We have described herein the details from the first two phase I clinical trials conducted with human adult volunteers under double blind, randomized conditions. The participants each received a single intramuscular injection to evaluate safety and initial immunogenicity. We have found an excellent safety profile and an antibody response similar to the one observed for the control vaccine.


Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/administración & dosificación , Haemophilus influenzae tipo b/inmunología , Adulto , Anticuerpos Antibacterianos/sangre , Especificidad de Anticuerpos , Método Doble Ciego , Ensayo de Inmunoadsorción Enzimática , Infecciones por Haemophilus/inmunología , Vacunas contra Haemophilus/efectos adversos , Vacunas contra Haemophilus/inmunología , Humanos , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Inmunoglobulina M/inmunología , Masculino , Estudios Retrospectivos , Prueba Bactericida de Suero , Vacunas Conjugadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA